Patient P-03070

Synthetic patientONX-7 · Day 147 · 45–54 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Favorable

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S14
Day 60 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 61 GI-04 recommended — GI Support Protocol GI-04
Day 62 Patient accepted — Started GI-04 in the companion
Day 70 GI symptom burden −29% vs expected — GI Support Protocol GI-04
Day 76 Tolerance state changed — Unstable → Improving
Day 80 ME-01 recommended — Monitoring Escalation ME-01
Day 81 Patient accepted — Started ME-01 in the companion
Day 84 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 60.

Primary contributors, last 14 days

GI instability+8
Nutritional resilience-7
Treatment adherence+4
Inflammatory activity+3
Toxicity-2

What helped?

GI Support Protocol GI-04Day 61
Result: symptom burden −29%
Monitoring Escalation ME-01Day 80
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

72%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 30/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
Autonomic recovery ↓40
- Wearable3,925 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓30
- Daily logGI symptom score 55 and rising
- WearableSleep 5.8 h, below personal baseline

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2 · butyrate capacity 30/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 55 ms
Sleep: 5.3 h
Steps: 4,817
Resting HR: 65 bpm

Daily log: GI score 55, nutritional resilience 42, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03146	59%	S14	GI-04	improved	53
P-03090	53%	S02	GI-04	improved	48
P-03300	52%	S14	GI-04	improved	46
P-03123	50%	S14	GI-04	improved	50
P-03145	47%	S14	GI-04	improved	51
P-03110	46%	S15	GI-04	improved	52
P-03323	44%	S14	GI-04	improved	48
P-03430	44%	S14	SC-12	improved	45
P-03037	39%	S14	NP-02	improved	43
P-03049	39%	S14	GI-04	improved	49
P-03226	38%	S05	GI-04	improved	43
P-03046	37%	S20	GI-04	no change	53